Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease

Ellis, 2001, Invasive fungal infections: evolving challenges for diagnosis and therapeutics, Mol Immunol, 38, 947, 10.1016/S0161-5890(02)00022-6

Kurnatowski, 2004, Selected risk factors of fungal infections in human populations, Wiad Parazytol, 50, 367

Wilson, 2002, The direct cost and incidence of systemic fungal infections, Value Health, 5, 26, 10.1046/j.1524-4733.2002.51108.x

Hope, 2005, Laboratory diagnosis of invasive aspergillosis, Lancet Infect Dis, 5, 609, 10.1016/S1473-3099(05)70238-3

Caillot, 1997, Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery, J Clin Oncol, 15, 139, 10.1200/JCO.1997.15.1.139

Von Eiff, 1995, Pulmonary aspergillosis: early diagnosis improves survival, Respiration, 62, 341, 10.1159/000196477

National Comprehensive Cancer Network. NCCN guidelines: prevention and treatment of cancer-related infections. www.nccn.org/professionals/physician_gls/f_guidelines.asp (accessed 2011 Jun 30).

Ullmann, 2007, Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease, N Engl J Med, 356, 335, 10.1056/NEJMoa061098

National Marrow Donor Program. Graft-versus-host disease. www.marrow.org/PATIENT/Survivorship_Ed/Treating_Complications/GVHD/index.html (accessed 2011 Jul 25).

Wingard, 1989, Predictors of death from chronic graft-versus-host disease after bone marrow transplantation, Blood, 74, 1428, 10.1182/blood.V74.4.1428.1428

Arias E . United States Life tables, 2002 national vital statistics report. www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_06.pdf(accessed 2011 Jul 25).

Healthcare Cost and Utilization Project. Overview of the Nationwide Inpatient Sample (NIS). www.hcup-us.ahrq.gov/nisoverview.jsp (accessed 2011 Jul 26).

Bureau of Labor Statistics. Consumer Price Index—all urban consumers. http://data.bls.gov/timeseries/CUUR0000SAM?output_view=pct_1mth (accessed 2011 Sep 6).

Menzin, 2009, Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients, Am J Health-Syst Pharm, 66, 1711, 10.2146/ajhp080325

AnalySource Online. www.analysource.com (accessed 2011 Jun 30).

Gold, 1996, Cost-effectiveness in health and medicine, 309, 10.1093/oso/9780195108248.001.0001

Drummond, 2001, Economic evaluation in health care. Chap. 8, 10.1093/oso/9780192631770.001.0001

Jansen, 2006, Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany, Value Health, 9, 12, 10.1111/j.1524-4733.2006.00076.x

Wenzel, 2005, Economic evaluation of voriconazole compared with conventional ampho-tericin B for the primary treatment of aspergillosis in immunocompromised patients, J Antimicrob Chemother, 55, 352, 10.1093/jac/dkh535

Dasbach, 2000, Burden of aspergillosis-related hospitalizations in the United States, Clin Infect Dis, 31, 1524, 10.1086/317487

Menzin, 2005, Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: findings from linked SEER-Medicare data, Value Health, 8, 140, 10.1111/j.1524-4733.2005.04004.x

Scharfstein, 1997, The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients, Med Decis Making, 17, 373, 10.1177/0272989X9701700402

Nomura, 2006, Cost-effectiveness of antifungal treatment for patients on chemotherapy, Eur J Cancer Care, 15, 44, 10.1111/j.1365-2354.2005.00618.x

De Vries, 2008, Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections, Pharmacoeconomics, 26, 75, 10.2165/00019053-200826010-00007